BFC Planning’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46.5K Sell
89
-947
-91% -$519K ﹤0.01% 1590
2026
Q2
$545K Buy
1,036
+176
+20% +$98.7K 0.02% 580
2026
Q1
$483K Sell
860
-2
-0.2% -$1.28K 0.02% 578
2025
Q4
$583K Buy
862
+729
+548% +$496K 0.03% 505
2025
Q3
$85K Buy
133
+28
+27% +$17K 0.01% 986
2025
Q2
$56.3K Sell
105
-7
-6% -$3.35K ﹤0.01% 1076
2025
Q1
$47K Buy
112
+1
+0.9% +$434 ﹤0.01% 1134
2024
Q4
$45.9K Sell
111
-236
-68% -$104K ﹤0.01% 1137
2024
Q3
$175K Buy
+347
New +$169K 0.02% 650

Other funds holding IDXX

BFC Planning's IDXX Position: Q3 2026 in Review

BFC Planning reduced its Idexx Laboratories (IDXX) stake by 91% in Q3 2026, selling an estimated $519K and leaving 89 shares worth $46.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

BFC Planning first reported a position in IDXX in Q3 2024 and has held it in 9 quarters since. The position peaked at $583K in Q4 2025. 1,104 funds tracked by Wall St. Rank hold IDXX as of Q3 2026.

  • BFC Planning held 89 shares of Idexx Laboratories worth $46.5K as of Q3 2026.
  • BFC Planning sold 947 Idexx Laboratories shares in Q3 2026, an estimated $519K.
  • Idexx Laboratories made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1590 holding.
  • BFC Planning first reported a position in Idexx Laboratories in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Idexx Laboratories position peaked at $583K in Q4 2025.
  • 1,104 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.